



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

ESMO Magnitude of Clinical Benefit Scale

Evaluation form 2c: for therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalence studies

Name of study:		
Study drug:	Indication:	
First author:	Year:	Journal:
Name of evaluator:		

Primary outcome is Toxicity or Quality of life AND Non-inferiority Studies

	<i>Mark with X if relevant</i>
Grade 4	
Reduced toxicity or improved QoL (using validated scale) with evidence for statistical non inferiority or superiority in PFS/OS	
Grade 3	
Improvement in some symptoms (using a validated scale) BUT without evidence of improved overall QoL	

Primary outcome is Response Rate

Grade 2	
RR is increased $\geq 20\%$ but no improvement in toxicity/QoL/PFS/OS	
Grade 1	
RR is increased $< 20\%$ but no improvement in toxicity/QoL/PFS/OS	

Final magnitude of clinical benefit grade

4	3	2	1